266 related articles for article (PubMed ID: 29566745)
1. Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis.
Weigold F; Günther J; Pfeiffenberger M; Cabral-Marques O; Siegert E; Dragun D; Philippe A; Regensburger AK; Recke A; Yu X; Petersen F; Catar R; Biesen R; Hiepe F; Burmester GR; Heidecke H; Riemekasten G
Arthritis Res Ther; 2018 Mar; 20(1):52. PubMed ID: 29566745
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3.
Recke A; Regensburger AK; Weigold F; Müller A; Heidecke H; Marschner G; Hammers CM; Ludwig RJ; Riemekasten G
Front Immunol; 2018; 9():428. PubMed ID: 29623076
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
4. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement.
Trombetta AC; Soldano S; Contini P; Tomatis V; Ruaro B; Paolino S; Brizzolara R; Montagna P; Sulli A; Pizzorni C; Smith V; Cutolo M
Respir Res; 2018 Sep; 19(1):186. PubMed ID: 30249259
[TBL] [Abstract][Full Text] [Related]
5. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
6. Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.
Bankamp L; Preuß B; Pecher AC; Beucke N; Henes J; Klein R
Front Immunol; 2021; 12():786039. PubMed ID: 34956217
[TBL] [Abstract][Full Text] [Related]
7. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.
Hanke K; Dähnrich C; Brückner CS; Huscher D; Becker M; Jansen A; Meyer W; Egerer K; Hiepe F; Burmester GR; Schlumberger W; Riemekasten G
Arthritis Res Ther; 2009; 11(1):R28. PubMed ID: 19232127
[TBL] [Abstract][Full Text] [Related]
9. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
[TBL] [Abstract][Full Text] [Related]
10. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies.
Markusse IM; Meijs J; de Boer B; Bakker JA; Schippers HPC; Schouffoer AA; Ajmone Marsan N; Kroft LJM; Ninaber MK; Huizinga TWJ; de Vries-Bouwstra JK
Rheumatology (Oxford); 2017 Jul; 56(7):1081-1088. PubMed ID: 27940596
[TBL] [Abstract][Full Text] [Related]
11. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease.
Truchetet ME; Brembilla NC; Montanari E; Allanore Y; Chizzolini C
Arthritis Res Ther; 2011; 13(5):R166. PubMed ID: 21996293
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
13. Identification of Autoimmunity to Peptides of Collagen V α1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis.
Velosa APP; Brito L; de Jesus Queiroz ZA; Carrasco S; Tomaz de Miranda J; Farhat C; Goldenstein-Schainberg C; Parra ER; de Andrade DCO; Silva PL; Capelozzi VL; Teodoro WR
Front Immunol; 2020; 11():604602. PubMed ID: 33643291
[TBL] [Abstract][Full Text] [Related]
14. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
15. The Th1 chemokine IP-10 in Systemic sclerosis.
Corrado A
Clin Ter; 2014; 165(6):e436-41. PubMed ID: 25524202
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
17. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
Kuwatsuka Y; Ogawa F; Iwata Y; Komura K; Muroi E; Hara T; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional study of soluble selectins, fractions of circulating microparticles and their relationship to lung and skin involvement in systemic sclerosis.
Iversen LV; Ullman S; Østergaard O; Nielsen CT; Halberg P; Karlsmark T; Heegaard NH; Jacobsen S
BMC Musculoskelet Disord; 2015 Aug; 16():191. PubMed ID: 26265409
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk.
De Luca G; Bosello SL; Berardi G; Rucco M; Canestrari G; Correra M; Mirone L; Forni F; Di Mario C; Danza FM; Pirronti T; Ferraccioli G
Rheumatology (Oxford); 2015 Nov; 54(11):1991-9. PubMed ID: 26106211
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage.
Ogawa F; Shimizu K; Hara T; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Takehara K; Sato S
Arch Dermatol Res; 2010 Jan; 302(1):27-35. PubMed ID: 19844733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
